REPL Replimune Group Inc.

18.78
0  0%
Previous Close 18.78
Open 18.55
Price To Book 3.48
Market Cap 688,205,307
Shares 36,645,650
Volume 166,687
Short Ratio
Av. Daily Volume 95,474
Stock charts supplied by TradingView

NewsSee all news

  1. Replimune to Provide Data Update on June 3, 2020

    WOBURN, Mass., April 30, 2020 (GLOBE NEWSWIRE) -- Replimune Group Inc. (NASDAQ:REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced it will

  2. Replimune Group, Inc. General Corporate Statement (Form8) (0001104659-20-043704)

  3. Replimune Appoints Dieter Weinand as Chairman and Paolo Pucci to the Board of Directors

    WOBURN, Mass., April 02, 2020 (GLOBE NEWSWIRE) -- Replimune Group Inc. (NASDAQ:REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced the

  4. Replimune Reports Third Fiscal Quarter Financial Results and Provides Corporate Update

    RP1: Four of the first five cutaneous squamous cell carcinoma (CSCC) patients treated in combination with Opdivo® reported to be in response (all ongoing) including two complete responses; registration-directed

  5. Replimune to Present at Two Upcoming Investor Conferences

    WOBURN, Mass., Feb. 06, 2020 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced that

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 1/2 update June 3, 2020.
RP1 and nivolumab
Melanoma
Phase 2 commencement of enrolment announced October 15, 2019.
RP1 and cemiplimab
Cutaneous squamous cell carcinoma (CSCC)
Phase 1 initial data due by the end of 2020.
RP2 and nivolumab
Solid tumors
Phase 1 trial to be initiated 1H 2020 with data due YE 2020.
RP1
Cutaneous squamous cell carcinoma (CSCC)
Phase 1 trial to be initiated 2020.
RP3

Latest News

  1. Replimune to Provide Data Update on June 3, 2020

    WOBURN, Mass., April 30, 2020 (GLOBE NEWSWIRE) -- Replimune Group Inc. (NASDAQ:REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced it will

  2. Replimune Group, Inc. General Corporate Statement (Form8) (0001104659-20-043704)

  3. Replimune Appoints Dieter Weinand as Chairman and Paolo Pucci to the Board of Directors

    WOBURN, Mass., April 02, 2020 (GLOBE NEWSWIRE) -- Replimune Group Inc. (NASDAQ:REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced the

  4. Replimune Reports Third Fiscal Quarter Financial Results and Provides Corporate Update

    RP1: Four of the first five cutaneous squamous cell carcinoma (CSCC) patients treated in combination with Opdivo® reported to be in response (all ongoing) including two complete responses; registration-directed

  5. Replimune to Present at Two Upcoming Investor Conferences

    WOBURN, Mass., Feb. 06, 2020 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced that

  6. Replimune Provides 2019 Year End Corporate Update and Reviews Expected 2020 Milestones

    RP1: Registration-directed randomized controlled Phase 2 clinical trial of RP1 in combination with cemiplimab-rwlc (Libtayo®) in cutaneous squamous cell carcinoma (CSCC) underway RP1: Study of RP1 as a monotherapy in

  7. Replimune Announces the Evolution of its Management Team as it Advances Through Later Stage Clinical Development and Prepares for Commercialization

    WOBURN, Mass., Jan. 09, 2020 (GLOBE NEWSWIRE) -- Replimune Group Inc. (NASDAQ:REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced the

  8. Replimune to Present at the 38th Annual J.P.Morgan Healthcare Conference

    WOBURN, Mass., Jan. 07, 2020 (GLOBE NEWSWIRE) -- Replimune Group Inc. (NASDAQ:REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced that Robert

  9. Replimune Strengthens Executive Team with the Appointment of Jean Franchi as Chief Financial Officer

    WOBURN, Mass., Dec. 09, 2019 (GLOBE NEWSWIRE) -- Replimune Group Inc. (NASDAQ:REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced the

  10. Replimune to Present at the Piper Jaffray 31st Annual Healthcare Conference

    WOBURN, Mass., Nov. 26, 2019 (GLOBE NEWSWIRE) -- Replimune Group Inc. (NASDAQ:REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced that Philip

  11. Replimune Announces Pricing of Public Offering

    BOSTON, Nov. 14, 2019 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced the pricing of its

  12. Replimune Announces Proposed Public Offering

    BOSTON, Nov. 12, 2019 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced a proposed public

  13. Replimune Reports Second Fiscal Quarter Financial Results and Provides Corporate Update

    RP1: Clinical data presented at the 34th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2019) confirmed expected safety profile and mechanism of action: Efficacy data supports ongoing and expanded

  14. Replimune Presents Initial Clinical Data with RP1 that Strongly Supports Expansion of Clinical Programs in Melanoma and Cutaneous Squamous Cell Carcinoma (CSCC)

    Data demonstrate RP1 alone and combined with Opdivo® is well tolerated with anti-tumor efficacy in target tumor types Mechanism of action confirmed for RP1 alone and in combination with Opdivo Biomarker

  15. Replimune to Host Investor Event at the 34th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

    WOBURN, Mass., Oct. 31, 2019 (GLOBE NEWSWIRE) -- Replimune Group Inc. (NASDAQ:REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced it will host

  16. Replimune Provides Update on RP1 Clinical Development Program in Cutaneous Squamous Cell Carcinoma

    First patient enrolled in registration-directed Phase 2 clinical trial of RP1 in combination with Regeneron and Sanofi's Libtayo® in CSCC New clinical trial planned of RP1 as monotherapy in organ transplant patients

  17. Replimune Announces Presentation at the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting

    WOBURN, Mass., Oct. 02, 2019 (GLOBE NEWSWIRE) -- Replimune Group Inc. (NASDAQ:REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, announced that data with the

  18. Replimune to Present at Chardan's 3rd Annual Genetic Medicines Conference

    WOBURN, Mass., Oct. 01, 2019 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced that Robert